Tirzepatide Monotherapy in Patients With Wolfram Syndrome Type 1

NCT05659368 on ClinicalTrials.gov · last registry update 2024-02-22

A small phase 2 — 10 participants, against a typical 110. Its estimated completion date, October 2024, has passed with no update to the record. Primary outcome, as filed: changing in endogenous insulin production. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here.

Status: UNKNOWN
Phase: P2
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Ospedale San Raffaele
Sponsor type: Other
Enrollment: 10
Started: 2024-01-01
Primary completion: 2024-10 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

changing in endogenous insulin production

Conditions studied

Wolfram Syndrome

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.